TTY Biopharm Company Limited (TPEX:4105)
77.00
+0.60 (0.79%)
Aug 19, 2026, 1:30 PM CST
TTY Biopharm Company Revenue
TTY Biopharm Company had revenue of 1.65B TWD in the quarter ending June 30, 2026, with 9.23% growth. This brings the company's revenue in the last twelve months to 6.65B, up 7.04% year-over-year. In the year 2025, TTY Biopharm Company had annual revenue of 6.45B with 9.49% growth.
Revenue (ttm)
6.65B
Revenue Growth
+7.04%
P/S Ratio
2.85
Revenue / Employee
19.46M
Employees
342
Market Cap
19.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.45B | 559.10M | 9.49% |
| Dec 31, 2024 | 5.89B | 388.31M | 7.05% |
| Dec 31, 2023 | 5.51B | 443.94M | 8.77% |
| Dec 31, 2022 | 5.06B | 526.00M | 11.60% |
| Dec 31, 2021 | 4.54B | 313.77M | 7.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 28.49B |
| Bora Pharmaceuticals | 19.56B |
| Grape King Bio | 10.28B |
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.08B |
| Synmosa Biopharma | 6.37B |
| ScinoPharm Taiwan | 3.07B |
| Center Laboratories | 1.66B |